fda warning letters compounded semaglutide tirzepatide september 2025 Lilly warns GLP-1 knockoffs may be 'dangerous,' escalating war with compounders NCL Issues a Second Alert
Description
Eli Lilly, the maker of Zepbound and Mounjaro, had pushed back against the OFAs assertion that shortages of tirzepatide were still in place, and has also claimed that versions of the drug made by compounded pharmacies are often untested, unapproved knockoffs, according to NBC News
However, researchers found that no new or liver-related safety signals emerged. Overall, the results of this study indicate that semaglutide may help improve liver outcomes for people with MASH
The nerve infarcts
Women should maintain open communication with their healthcare providers about reproductive health changes throughout treatment
Plaintiffs allege that Novo Nordisk, the drugs manufacturer, failed to adequately warn patients and healthcare providers of these risks
Your care team will keep you updated throughout the process.
